Researchers at the Weizmann Institute of Science have engineered a plant capable of producing several psychedelic substances simultaneously [1].
This breakthrough allows scientists to concentrate compounds that naturally occur in different species into a single biological system. The ability to manufacture these substances in a controlled environment could accelerate the development of new pharmaceutical treatments for mental health disorders.
The team deciphered the complex biological processes required to create these substances [1]. By understanding the chemical pathways, they were able to engineer a plant to produce five psychedelic substances [1] that are typically scattered across the tree of life [1]. These compounds are naturally found in a variety of plants, fungi, and animals [2].
Historically, these mind-altering substances were used in rituals, healing practices, and mental health treatment long before they were studied in a laboratory setting, a researcher said [2]. The current engineering feat represents a shift from gathering these materials in the wild to synthesizing them through biotechnology.
By teaching plants to create these rare compounds, the researchers believe they are opening new possibilities for medicine, a scientist said [3]. The process involves manipulating the plant's genetic machinery to replicate the synthesis found in other organisms.
The project focused on the unification of these diverse chemical signatures. By bringing these five substances together in one organism, the researchers have created a more efficient method for studying how these compounds interact and how they might be utilized in clinical settings [1].
“Scientists taught plants to make rare psychedelic compounds from plants, fungi, and animals, opening new possibilities for medicine.”
This development marks a transition from the discovery of naturally occurring psychoactive compounds to the precision engineering of biological factories. By consolidating multiple psychedelic substances into a single plant, researchers can bypass the ecological and logistical challenges of harvesting rare species. This may lead to more standardized, scalable production of compounds for psychiatric research and the creation of hybrid therapies.
